Related references
Note: Only part of the references are listed.Fludarabine increases nuclease-free AAV- and CRISPR/Cas9-mediated homologous recombination in mice
Shinnosuke Tsuji et al.
NATURE BIOTECHNOLOGY (2022)
DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing
Chaoyou Xue et al.
TRENDS IN GENETICS (2021)
Targeting the Apoa1 locus for liver-directed gene therapy
Marco De Giorgi et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)
Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B
Lindsey A. George et al.
MOLECULAR THERAPY (2020)
CRISPR-Cas9-Mediated In Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice
Qingnan Wang et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Genome editing technologies to treat rare liver diseases
Marta Trevisan et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice
Lili Wang et al.
BLOOD (2019)
Engineered materials for in vivo delivery of genome-editing machinery
Sheng Tong et al.
NATURE REVIEWS MATERIALS (2019)
Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases
Alessia De Caneva et al.
JCI INSIGHT (2019)
A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing
Jonathan D. Finn et al.
CELL REPORTS (2018)
Emerging Issues in AAV-Mediated In Vivo Gene Therapy
Pasqualina Colella et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice
Cong Huai et al.
HUMAN GENETICS (2017)
Hit and go CAS9 delivered through a lentiviral based self-limiting circuit
Gianluca Petris et al.
NATURE COMMUNICATIONS (2017)
CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice
Tsukasa Ohmori et al.
SCIENTIFIC REPORTS (2017)
Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector
Ziqing Liu et al.
SCIENTIFIC REPORTS (2017)
Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model
Fabiola Porro et al.
EMBO MOLECULAR MEDICINE (2017)
Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors
Amine Meliani et al.
BLOOD ADVANCES (2017)
CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse
Yuting Guan et al.
EMBO MOLECULAR MEDICINE (2016)
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang Yang et al.
NATURE BIOTECHNOLOGY (2016)
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo
Hao Yin et al.
NATURE BIOTECHNOLOGY (2016)
In vivo genome editing of the albumin locus as a platform for protein replacement therapy
Rajiv Sharma et al.
BLOOD (2015)
Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells
Jake Chng et al.
MABS (2015)
Therapeutic genome editing: prospects and challenges
David Benjamin Turitz Cox et al.
NATURE MEDICINE (2015)
Promoter less gene targeting without nucleases ameliorates haemophilia B in mice
A. Barzel et al.
NATURE (2015)
Genome Engineering with Targetable Nucleases
Dana Carroll
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 83 (2014)
Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
Suresh Ramakrishna et al.
GENOME RESEARCH (2014)
Life-Long Correction of Hyperbilirubinemia with a Neonatal Liver-Specific AAV-Mediated Gene Transfer in a Lethal Mouse Model of Crigler-Najjar Syndrome
Giulia Bortolussi et al.
HUMAN GENE THERAPY (2014)
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
A. C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Hepatic Gene Transfer in Neonatal Mice by Adeno-Associated Virus Serotype 8 Vector
Lili Wang et al.
HUMAN GENE THERAPY (2012)
Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid Proteins
Amit C. Nathwani et al.
MOLECULAR THERAPY (2011)
High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice
Jin Hee Kim et al.
PLOS ONE (2011)
Generation of a novel factor IX with augmented clotting activities in vitro and in vivo
C. N. Lin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Gene delivery to the juvenile mouse liver using AAV2/8 vectors
Sharon C. Cunningham et al.
MOLECULAR THERAPY (2008)
Inhibitor development in haemophilia B: an orphan disease in need of attention
Donna DiMichele
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Definitions in hemophilia - Recommendation of the Scientific Subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
GC White et al.
THROMBOSIS AND HAEMOSTASIS (2001)
Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver
LL Wang et al.
MOLECULAR THERAPY (2000)
Share Paper
